This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A New Class of Antihypertensive Drugs

John H. Bauer, MD; Garry P. Reams, MD

Arch Intern Med. 1995;155(13):1361-1368.

Abstract
The angiotensin II (AII) type 1 receptor antagonists represent a new pharmacologic class of drugs that are specifically designed to displace All from its type 1 receptor subtype. These drugs antagonize AII-induced biologic actions, including smooth-muscle contraction, sympathetic pressor mechanisms, and aldosterone release. Initial clinical trials suggest that these drugs are effective in the treatment of essential hypertension and hypertensive patients with intrinsic renal disease. Thus, they are the newest addition to the therapeutic armamentarium for the treatment of hypertensive diseases. We review the developmental history and pharmacology of the All type 1 receptor antagonists. We specifically discuss the following factors: mechanism(s) of action; members under clinical investigation; effects on renal function, salt and water excretion, and plasma renin activity, plasma All type 1, and plasma aldosterone concentrations; and efficacy and safety. Given the demonstrable benefits of All type 1 receptor blockade, these drugs should achieve broad utility in the treatment of hypertensive diseases.

(Arch Intern Med. 1995;155:1361-1368)

Author Affiliations
From the Medical Service, Harry S Truman Memorial Veterans Hospital, and the Department of Internal Medicine, University of Missouri School of Medicine, Columbia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Nickenig et al.
Journal of Renin-Angiotensin-Aldosterone System 2006;7:S1-S7.
ABSTRACT  

Upregulation of Immunoreactive Angiotensin II Release and Angiotensinogen mRNA Expression by High-Frequency Preganglionic Stimulation at the Canine Cardiac Sympathetic Ganglia
Kushiku et al.
Circ. Res. 2001;88:110-116.
ABSTRACT | FULL TEXT  

Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim and Iwao
Pharmacol. Rev. 2000;52:11-34.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of Combination of Perindopril, Candesartan, and Amlodipine in Hypertensive Rats
Kim et al.
Hypertension 2000;35:769-774.
ABSTRACT | FULL TEXT  

Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension
Marino et al.
J CARDIOVASC PHARMACOL THER 1999;4:67-75.
ABSTRACT  

Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure
Brodsky et al.
Hypertension 1998;32:746-752.
ABSTRACT | FULL TEXT  

ACE Inhibitors as a Shield Against Diabetic Nephropathy
Materson
Arch Intern Med 1996;156:239-240.
ABSTRACT  

Losartan and Severe Migraine
Ahmad
JAMA 1995;274:1266-1267.
ABSTRACT